Shire (SHP)

 

SHP Share PerformanceMore

52 week high5,067.0 03/03/17
52 week low3,435.5 27/10/17
52 week change -740.5 (-16.44%)
4 week volume52,487,403 19/11/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)

YASTEST

Shire plc : Directorate change

Shire plc: Directorate change Chief Financial Officer update December 8, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, announced on August 21, 2017, that Jeff Poulton, Chief Financial Officer, would leave Shire at the end of the year. On November 20, 2017, Shire announced that Thomas Dittrich will join the company as Chie...

Shire and Rani enter into collaboration agreement

Shire and Rani Therapeutics have confirmed that they have entered into a collaboration agreement to evaluate the use of t...

Shire and Rani Therapeutics Enter into Collaboration to Evaluate Use of the Rani Pill(TM) Technology for the Oral Delivery of Factor Therapy

YASTEST

Shire plc : Total voting rights

Shire plc: Total voting rights Total Voting Rights December 1, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and Transparency Rules, notifies the market of the following: As at November 30, 2017, the Company's issued ordinary share capital comprised 909...

Shire appoints new R&D head

Shire has appointed Andreas Busch as executive vice president, head of research and development and chief scientific offic...

Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer

Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer Howard Mayer, MD to become Chief Medical Officer Cambridge, MA - December 1, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in...

U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric Patients

YASTEST

Latest discussion posts More

  • Re: Why over 6% rise in SP today?

    "When the market starts to focus on that and not the debt you wont see this for dust." I'd like to see some dust as this is my second biggest holding. Games
    22-Nov-2017
    gamesinvestor
  • Re: Why over 6% rise in SP today?

    Hope you're right about not seeing it for dust, SM, just bought a shedload
    17-Nov-2017
    lotcangorong
  • Re: Why over 6% rise in SP today?

    It could have something to do with the fact that this is heavily oversold. This is a growth story with a credible pipeline. It's also generating plenty of cash. When the ...
    16-Nov-2017
    sound money

Users' HoldingsMore

Users who hold Shire also hold..

Codes & Symbols

ISINJE00B2QKY057
SymbolsSHP, LSE:SHP, SHP.L, SHP:LN, LON:SHP, XLON:SHP

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account